Corbenic Partners’s Amgen AMGN Stock Holding History

Corbenic Partners’s Portfolio AMGN Stock Details AMGN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q4	–	Sell	-13	Closed	-$3K	–	277
2021 Q3	$3K	Buy	+13	New	+$2.99K	﹤0.01%	222

Other funds holding AMGN

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Charles Schwab San Francisco, California $654B AUM 26.35% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Corbenic Partners's AMGN Position: Q4 2021 in Review

Corbenic Partners sold out of Amgen (AMGN) in Q4 2021, closing a stake of 13 shares — an estimated $3K sold.

Corbenic Partners first reported a position in AMGN in Q3 2021 and held it in 1 quarter. The position peaked at $3K in Q3 2021. 2,293 funds tracked by Wall St. Rank hold AMGN as of Q4 2021.

Corbenic Partners reported no remaining Amgen position as of Q4 2021 after selling out during the quarter.
Corbenic Partners sold 13 Amgen shares in Q4 2021, an estimated $3K.
Corbenic Partners first reported a position in Amgen in Q3 2021 and held it in 1 quarter.
Corbenic Partners's Amgen position peaked at $3K in Q3 2021.
2,293 funds tracked by Wall St. Rank held Amgen as of Q4 2021.

Based on Corbenic Partners's 13F filing for Q4 2021, filed 21 Jan 2022.